Hacker News with Generative AI: Drug Repurposing

Cure ID App Lets Clinicians Report Novel Uses of Existing Drugs (fda.gov)
The case for clinical trial abundance (ifp.org)
In 2014, the first SGLT2 inhibitor, dapagliflozin, was approved for patients with Type II diabetes for the control of blood glucose levels. Since then, the list of indications for this class of molecules has expanded to include kidney disease (2021) and heart failure (2020) in non-diabetics, both important sources of morbidity and mortality. Despite being an already developed drug with safety data, these repurposings took seven and six years, respectively.